Table 3. External consistency: comparison with similar studies.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| First author, year | Country | Study perspective | Population | Time horizon | ICER | PSA |
| Bresse X.,2013 [8] | France | TPP; societal | People aged 70-79 and 65+ | Lifetime | **TPP**: 70-79: €9,513/QALY; 65 + : € 12,304/QALY. **Societal**:70-79: €14,198/QALY; 65+: €18,385/QALY | 99% cost effective |
| Moore L., 2010 [9] | UK | TPP; societal | People aged 50+, 50-54, 55-59, 60-64, 65-69, 70+ | Lifetime | **TPP**: 50+: € 15,559/QALY; 50-54: €15,403/QALY55-59: € 13, 815/QALY60-64: € 12,747/QALY;65-69: € 11,924 /QALY. **Societal**:50+: € 13,584/QALY; 50-54: €10,662/QALY55-59: € 10,351/QALY60-64: € 10,984/QALY65-69: € 11,644/QALYICERs remain less than the threshold £30,000/QALY gained for persons aged less than 85.The ICERs of the two perspectives are identical after the age of 70 as there are no productivity losses after this age. | 92,7% cost effective |
| Annemans L., 2010 [10] | Belgium | TPP; healthcare; societal | People aged 60 + and 50+, 65+, 60-64, 65-69, 60-69 | Lifetime | **TPP**: 60+: € 6,799/QALY;50+: € 6,614/QALY;65+: €7,173/QALY;60-64: € 5,686/QALY;65-69: € 5,404/QALY;60-69: € 5,545/QALY;**Healthcare:** 60+: € 7,169/QALY;50+: €6,966/QALY;65+: € 7,575/QALY;60-64: € 5,953/QALY;65-69:€ 5,647/QALY;60-69: € 5,800/QALY**Societal:** 60+: € 7,137/QALY;50+: €6,812/QALY;65+: €7,566/QALY;60-64: € 5,858/QALY;65-69: €5,629/QALY;60-69: € 5,739/QALY | 94% cost-effective |
| Szucs T., 2011 [11] | Switzerland | TPP; societal | People aged 70-79; 60–69, 65+ and 75+ | Lifetime | **TPP**: 70-79. € 18,250/QALY; 60-69: € 14,849/QALY; 65+ : € 21,412/QALY;75+: € 25,394/QALY**Societal**: 70-79: € 20,399/QALY; 60-69: € 16,417/QALY; 65+: €23,892/QALY;75+: € 28,357/QALY | N.A. |

TPP: Thirdy party payer

N.A.: Not applicable